{"protocolSection": {"identificationModule": {"nctId": "NCT00104416", "orgStudyIdInfo": {"id": "LAM100036"}, "organization": {"fullName": "GlaxoSmithKline", "class": "INDUSTRY"}, "briefTitle": "Study Evaluating LAMICTAL Extended-Release Therapy Added To Current Seizure Treatments In Patients With Primary Generalized Tonic-Clonic Seizures (PGTC) Seizures", "officialTitle": "A Multicenter, Double-blind, Randomized, Parallel-group Evaluation of LAMICTAL Extended-Release Adjunctive Therapy in Patients With Primary Generalized Tonic-Clonic Seizures"}, "statusModule": {"statusVerifiedDate": "2016-11", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2004-12"}, "primaryCompletionDateStruct": {"date": "2008-07", "type": "ACTUAL"}, "completionDateStruct": {"date": "2008-07", "type": "ACTUAL"}, "studyFirstSubmitDate": "2005-02-28", "studyFirstSubmitQcDate": "2005-02-28", "studyFirstPostDateStruct": {"date": "2005-03-01", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2010-04-16", "resultsFirstSubmitQcDate": "2010-04-16", "resultsFirstPostDateStruct": {"date": "2010-05-18", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2016-11-15", "lastUpdatePostDateStruct": {"date": "2017-01-02", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "GlaxoSmithKline", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "This study is being conducted to compare the efficacy and safety of LAMICTAL (lamotrigine) extended-release with placebo in the treatment of Primary Generalized Tonic-Clonic (PGTC) seizures. LAMICTAL extended-release is an investigational drug. Placebo tablets look like LAMICTAL extended-release tablets but do not contain active medication. In this study, LAMICTAL extended-release or placebo tablets will be added to current seizure treatments."}, "conditionsModule": {"conditions": ["Epilepsy, Tonic-Clonic"], "keywords": ["antiepileptic drugs", "seizures", "primary generalized tonic-clonic seizures", "Epilepsy", "lamotrigine", "anticonvulsants", "LAMICTAL"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 153, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Placebo", "type": "PLACEBO_COMPARATOR", "interventionNames": ["Drug: Placebo"]}, {"label": "lamotrigine (LAMICTAL) extended-relesase", "type": "EXPERIMENTAL", "interventionNames": ["Drug: lamotrigine (LAMICTAL) extended-release"]}], "interventions": [{"type": "DRUG", "name": "lamotrigine (LAMICTAL) extended-release", "description": "Primary experimental dosage form", "armGroupLabels": ["lamotrigine (LAMICTAL) extended-relesase"]}, {"type": "DRUG", "name": "Placebo", "description": "Placebo control", "armGroupLabels": ["Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Percent Change From Baseline in Weekly Primary Generalized Tonic-clonic (PGTC) Seizure Frequency During the Entire Double-Blind Treatment Phase", "description": "Percent change from baseline is calculated as the number of seizures by week during the Double-Blind Treatment Phase (Treatment Week 1 up to Week 19) compared to the number of seizures per week during the Baseline Phase (Baseline Week 1 up to Week 8). A positive number equals a reduction in seizure frequency. PGTC seizures are more commonly known as gran mal seizures.", "timeFrame": "Baseline through end of Double-Blind Treatment Phase (up to Week 19)"}], "secondaryOutcomes": [{"measure": "Number of Participants With >=25%, >=50%, >=75%, or 100% Reduction in PGTC Seizure Frequency During the Entire Double-Blind (DB)Treatment Phase (TP), the Escalation Phase, the Maintenance Phase, and the Last 8 Weeks of the Maintenance Phase", "description": "Change in seizure frequency was calculated as the average seizure frequency during each of the following: the Entire DB Treatment Phase (Treatment Week 1 up to Week 19); the Escalation Phase (Treatment Week 1 up to Week 7); the Maintenance Phase (Treatment Week 8 up to Week 19); and the last 8 weeks of the Maintenance Phase (Treatment Week 12 up to Week 19), minus the seizure frequency at Baseline.", "timeFrame": "Entire DB Treatment Phase (Treatment Week 1 up to Week 19), Escalation Phase (Treatment Week 1 up to Week 7), Maintenance Phase (Treatment Week 8 up to Week 19), and the last 8 weeks of the Maintenance Phase (Treatment Week 12 up to Week 19)"}, {"measure": "Percent Change From Baseline in PGTC Seizure Frequency During the Escalation Phase, the Maintenance Phase, and During the Last 8 Weeks of the Maintenance Phase of the Double-Blind Treatment Phase", "description": "Percent change from baseline is calculated as the number of seizures by week during the Escalation Phase (Treatment Week 1 up to Week 7), the Maintenance Phase (Treatment Week 8 up to Week 19), and during the last 8 weeks of the Maintenance Phase (Treatment Week 12 up to Week 19) compared to the number of seizures per week during the Baseline Phase (Baseline Week 1 up to Week 8). A positive number equals a reduction in seizure frequency.", "timeFrame": "Escalation Phase (Treatment Week 1 up to Week 7), Maintenance Phase (Treatment Week 8 up to Week 19), and the last 8 weeks of the Maintenance Phase (Week 12 up to Week 19)"}, {"measure": "Number of Participants With the Indicated Time to >=50% Reduction in Seizure Frequency in the Double-Blind Treatment Phase", "description": "50% reduction in seizure frequency is defined as the time at which a participant first achieved and maintained a \\>=50% reduction in seizure frequency following exposure to at least 1 week of study drug.", "timeFrame": "Baseline through end of Double-Blind Treatment Phase (up to Week 19)"}, {"measure": "Change From Baseline in Body Weight at Week 19 of the Double-Blind Treatment Phase", "description": "Change from baseline in body weight is calculated as the Week 19 (or last on-study measurement in Double-Blind Treatment Phase) value minus the Baseline value.", "timeFrame": "Baseline and Week 19 (or last on-study measurement in Double-Blind Treatment Phase)"}, {"measure": "Number of Participants With Improved Clinical Status on the Investigator's Global Assessment in the Double-Blind Treatment Phase", "description": "The investigators rated the participants' overall clinical status based on 7 clinical factors and an overall factor: seizure frequency, duration, and intensity; adverse experiences; social, intellectual, and motor functioning. Using a 7-point scale (marked deterioration \\[1\\], moderate deterioration \\[2\\], mild deterioration \\[3\\], no change \\[4\\], mild improvement \\[5\\], moderate improvement \\[6\\], or marked improvement \\[7\\]), the investigators assessed the participants' status compared to their condition prior to initiating study medication.", "timeFrame": "Week 19 (or last on-study assessment in Double-Blind Treatment Phase)"}, {"measure": "Number of Participants With Improved Satisfaction With Seizure Control on the Subject Satisfaction Questionnaire in the Double-Blind Treatment Phase", "description": "Participants were asked to rate their satisfaction with their seizure control compared to their seizure control prior to initiating study drug on a 7 point scale: marked deterioration (1), moderate deterioration (2), mild deterioration (3), no change (4), mild improvement (5), moderate improvement (6), or marked improvement (7).", "timeFrame": "Week 19 (or last on-study assessment in Double-Blind Treatment Phase)"}, {"measure": "Percent Change From Baseline in Weekly PGTC Seizure Frequency During the Entire Continuation Phase (CP), the Transition Phase, the Open-Label Phase, and the Last 8 Weeks of the Open-Label Phase", "description": "Percent change from baseline is calculated as the number of seizures by week during the entire CP (CP Week 1 up to Week 52), the Transition Phase (CP Week 1 up to Week 7), the Open-Label Phase (CP Week 8 up to Week 52), and the last 8 weeks of the Open-Label Phase (CP Week 45 up to Week 52) minus the number of seizures per week during the Baseline Phase (Baseline Week 1 through Week 8). A positive number equals a reduction in seizure frequency.", "timeFrame": "Entire CP (CP Week 1 up to Week 52), the Transition Phase (CP Week 1 up to Week 7), the Open-Label Phase (CP Week 8 up to Week 52), and the last 8 weeks of the Open-Label Phase (CP Week 45 up to Week 52)"}, {"measure": "Number of Participants With >=25%, >=50%, >=75%, or 100% Reduction or >=50% Increase From Baseline in Weekly PGTC Seizure Frequency for the Entire Continuation Phase, the Transition Phase, the Open-Label (OL) Phase, and the Last 8 Weeks of the OL Phase.", "description": "Change in seizure frequency was calculated as the average seizure frequency during each of the following: the Entire CP (CP Week 1 up to Week 52); the Transition Phase (CP Week 1 up to Week 7); the Open-Label (OL) Phase (CP Week 8 up to Week 52); and the last 8 weeks of the Open Label Phase (CP Week 45 up to Week 52) minus the seizure frequency at Baseline. W, Week.", "timeFrame": "Entire CP (CP Week 1 up to Week 52), the Transition Phase (CP Week 1 up to Week 7), the Open-Label Phase (CP Week 8 up to Week 52), and the last 8 weeks of the Open-Label Phase (CP Week 45 up to Week 52)"}, {"measure": "Mean Change From Baseline in the Profile of Mood State (POMS) Mood Disturbance Total Score at Week 19 of the Double-Blind Treatment Phase", "description": "The POMS is a self-administered 65-item questionnaire that evaluates the participants' perception of their mood state in 6 areas: tension-anxiety, depression-dejection, anger-hostility, vigor-activity, fatigue-inertia, and confusion-bewilderment. Items are rated on a 5-point Likert scale from 0 (not at all) to 4 (extremely), with higher scores indicating a more negative mood state. A total score (from 0 to 24) is obtained by summing the scores of the six domains.", "timeFrame": "Baseline and Week 19 (or last on-study measurement in Double-Blind Treatment Phase)"}, {"measure": "Mean Change From Baseline in the Center for Epidemiological Studies-Depression Scale (CES-D) Total Score at Week 19 of the Double-Blind Treatment Phase", "description": "The 20-item CES-D questionnaire is self-administered and asks respondents to report the frequency to which the 20 events were experienced over the past week. A 4-point Likert scale is used and ranges from rarely or none of the time (0) to most or all of the time (3). The total score, a sum across the 20 items (ranging from 0 to 60), determines the extent to which a participant may be experiencing depression. Higher scores indicate a higher severity of depression.", "timeFrame": "Baseline and Week 19 (or last on-study measurement in Double-Blind Treatment Phase)"}, {"measure": "Mean Change From Baseline in the Neurological Disorders Depression Inventory-Epilepsy (NDDI-E) 6-Item Total Score at Week 19 of the Double-Blind Treatment Phase", "description": "The NDDI-E is a self-reported questionnaire composed of 46 brief phrases/words to identify mood disorders across the spectrum of depression. It was developed to capture depressive moods that are co-morbid with the disease of epilepsy or its treatment as well as to measure the depressive state of the participant. All phrases are measured on a 4-point Likert scale of Never (1) to Always/often (4) and refer to the participants' mood over the past week. Scoring is comprised of a total mood score calculated by summing the scores of 6 specific items (from 6=never to 24=always or often).", "timeFrame": "Baseline and Week 19 (or last on-study measurement in Double-Blind Treatment Phase)"}, {"measure": "Mean Change From Baseline in the Quality of Life in Epilepsy-31-P (QOLIE-31P) Overall Score at Week 19 of the Double-Blind Treatment Phase", "description": "The QOLIE-31 is a 31-item questionnaire that evaluates the participants' perception of his or her quality of life in 7 domains: seizure worry, emotional well being, energy/fatigue, cognitive functioning, medication effects, social functioning, and overall quality of life. Each domain (with scores ranging from 0 to 100) is summed and divided by the total number of questions that were answered. The overall score is derived by weighting and then summing up the seven domain scores.", "timeFrame": "Baseline and Week 19 (or last on-study measurement in Double-Blind Treatment Phase)"}, {"measure": "Mean Change From Baseline in the Adverse Experience Profile (AEP) Total Score at Week 19 of the Double-Blind Treatment Phase", "description": "The AEP is a list of 19 items covering many possible side effects attributable to drug treatment. The participants respond by assessing how much each event has been a problem for them over the past 4 weeks (1=Never a Problem to 4=Always a Problem). Each individual item can be examined; an overall adverse events score is calculated as the sum of the scores across the 19 items. The AEP total score ranges from 19 to 76, with a higher score indicating a higher degree of adverse event severity.", "timeFrame": "Baseline and Week 19 (or last on-study measurement in Double-Blind Treatment Phase)"}, {"measure": "Mean Change From Baseline in the Seizure Severity Questionnaire (SSQ) Global Bother Score at Week 19 Double-Blind Treatment Phase", "description": "The SSQ is a self-reported instrument developed to assess the severity of seizures and seizure symptoms. The scale consists of 10 major clinical features/symptoms of seizures that the participants rate on a 7-point Likert scale (ranging from very mild/helpful/no bother at all \\[1\\] to very severe/no help/bothersome \\[7\\]). The Global Bother Domain is the primary score used for the analysis of the SSQ and has scores ranging from 1 to 7.", "timeFrame": "Baseline and Week 19 (or last on-study measurement in Double-Blind Treatment Phase)"}, {"measure": "Mean Change From Baseline in the Epworth Sleepiness Scale (ESS) 8-Item Total Score at Week 19 of the Double-Blind Treatment Phase", "description": "The ESS is an 8-item, self-administered questionnaire that measures excessive daytime sleepiness in adults. The instrument captures information on the extent to which the participant would be likely, or not, to fall asleep in certain situations. The stimulus question is: How likely are you to doze off or fall asleep in the following situations, in contrast to feeling just tired? Questions are answered on a 4-point scale (would never doze \\[0\\] to high chance of dozing \\[3\\]). The total score ranges from 0 to 24, where a higher score indicates a higher chance of dozing.", "timeFrame": "Baseline and Week 19 (or last on-study measurement in Double-Blind Treatment Phase)"}, {"measure": "Serum Concentrations and Population (POP) Pharmacokinetic Parameters for Lamotrigine", "description": "Serum samples for participants on lamotrigine were analyzed with a validated analytical method based on solid phase extraction of serum followed by High-Performance Liquid Chromatography (HPLC) Mass Spectrometry (MS)/MS analysis. The lower limit of quantification (LLQ) for serum lamotrigine was 4 nanograms (ng)/milliliter (mL), using a 50 microliter (\u00b5L) aliquot of human serum with a higher limit of quantification (HLQ) of 4,000 ng/mL. PK data cannot be reported, as PK data from several different studies have been combined into one POP/PK analysis and cannot be separated by study.", "timeFrame": "Blood samples drawn at Treatment Weeks 11, 15, and 19 (or last on-study measurement in Double-Blind Treatment Phase)"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Is \u226513 years of age (male or female).\n* Has a confident diagnosis of epilepsy with PGTC seizures for more than 24 weeks prior to the Baseline Phase.\n* Has electroencephalogram (EEG) evidence of either spike-and-wave discharges consistent with PGTC, or at least 2 EEGs with no indication of focal abnormalities. The EEG may be historical or prospective. Investigators may use a historical EEG as long as there is appropriate documentation.\n* Has a documented history of PGTC seizures with or without other generalized seizure type(s) with no focal onset, and at least 1 PGTC seizure during the eight consecutive weeks (i.e., 56 consecutive days) prior to starting the 8-week Baseline Phase.\n* Has at least 3 PGTC seizures occurring anytime during an 8-week (i.e., 56 days) prospective Baseline Phase.\n\n  * NOTE: When a historical baseline is used, the same time period cannot count for documentation of inclusion criteria 4 and 5. Additionally, innumerable seizure activity will not count towards the number of seizures required for randomization.\n  * NOTE: With authorization from GSK, a maximum of four weeks (i.e., 28 days) of historical seizure data may replace up to four weeks (i.e., 28 days) of the prospective Baseline Phase for subjects providing reliable documentation of the following:\n\n    1. complete daily seizure diary that includes the number of seizures experienced each day along with the exact classification of each seizure type for consecutive days prior to the prospective Baseline Phase\n    2. stability of prescribed dosages of background antiepileptic drugs (AEDs)\n    3. compliance with background AEDs.\n  * All subjects permitted to use historical seizure data must complete a minimum of four weeks (i.e., 28 days) of the prospective Baseline Phase. The historical Baseline Phase and the prospective Baseline Phase must equal 56 consecutive days.\n* Is currently treated with a stable regimen of one or two AED(s) for at least four weeks prior to starting the Baseline Phase (historical or prospective).\n\n  * NOTE: Benzodiazepines used chronically will be considered to be concurrent AEDs.\n  * NOTE: Subjects with surgically implanted vagal nerve stimulators (VNS) will be allowed to enter the study provided that all of the following conditions are met:\n\n    1. VNS has been in place for at least 24 weeks prior to the Baseline Phase.\n    2. The settings must remain the same for at least 28 days prior to the Baseline Phase.\n    3. The settings must remain the same during the Baseline, Escalation, Maintenance and Transition Phases.\n    4. The battery is expected to last for the duration of the study.\n    5. VNS is counted as a \"concurrent AED.\"\n* Is able and willing to maintain an accurate and complete daily written seizure diary, or has a parent/caregiver who is able and willing to maintain an accurate and complete daily written seizure diary for the entire duration of the study.\n* Is able to comply with dosing of study drugs, background AEDs and all study procedures.\n* Has given written informed consent, or has a parent/legally authorized representative who has given written informed consent, prior to the performance of any study assessments.\n* If female, and of childbearing potential, must be using an acceptable form of birth control, to include one of the following:\n\n  1. Complete abstinence from intercourse for two weeks before exposure to the study drug, throughout the clinical trial, and for a period after the trial to account for elimination of the drug (a minimum of 3 weeks).\n  2. Consistent and correct use of one of the following methods of birth control:\n\n     * Male partner who is sterile prior to the female subject's entry into the study and is the sole sexual partner for that female subject\n     * Implants of levonorgestrel\n     * Injectable progestogen\n     * Oral contraceptive (either combined, with at least 50mcg estrogen for women on enzyme-induced AEDs, or progestogen only)\n     * Any intrauterine device (IUD) with a documented failure rate of less than 1% per year\n     * Double barrier method consisting of spermicide plus a mechanical barrier (e.g., spermicide plus a male condom or a female diaphragm).\n     * NOTE: Women who have had a hysterectomy, tubal ligation, or are post-menopausal are considered to be of non-childbearing potential.\n\nExclusion Criteria:\n\n* Has a history of partial seizures or interictal expression of partial seizures as evidenced by EEG NOTE: EEG may be historical or prospective.\n* Has had status epilepticus within the 24 weeks prior to, or during, the Baseline Phase.\n* Is taking three or more background AEDs chronically.\n* Has Lennox-Gastaut syndrome.\n* Is currently using or has previously used lamotrigine.\n* Is currently taking felbamate.\n* Is abusing alcohol and/or other substance(s).\n* Has taken an investigational drug within the previous 30 days or plans to take an investigational drug anytime during the study.\n* Is receiving chronic treatment with any medication that could influence seizure control. NOTE: Use of benzodiazepines is allowed.\n* Is currently following the ketogenic diet.\n* Is planning surgery to control seizures during the study.\n* Is suffering from acute or progressive neurological disease, severe psychiatric disease, or severe mental abnormality that are likely to interfere with the objectives of the study.\n* Has any clinically significant cardiac, renal, hepatic condition, or a condition that affects the absorption, distribution, metabolism or excretion of drugs.\n* Is pregnant, breastfeeding, or planning to become pregnant during the study or within the three weeks after the last dose of study drug.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "13 Years", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "GSK Clinical Trials", "affiliation": "GlaxoSmithKline", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "GSK Investigational Site", "city": "Anniston", "state": "Alabama", "zip": "36207", "country": "United States", "geoPoint": {"lat": 33.65983, "lon": -85.83163}}, {"facility": "GSK Investigational Site", "city": "Birmingham", "state": "Alabama", "zip": "35294-0021", "country": "United States", "geoPoint": {"lat": 33.52066, "lon": -86.80249}}, {"facility": "GSK Investigational Site", "city": "Northport", "state": "Alabama", "zip": "35476", "country": "United States", "geoPoint": {"lat": 33.22901, "lon": -87.57723}}, {"facility": "GSK Investigational Site", "city": "Tuscaloosa", "state": "Alabama", "zip": "35406", "country": "United States", "geoPoint": {"lat": 33.20984, "lon": -87.56917}}, {"facility": "GSK Investigational Site", "city": "Phoenix", "state": "Arizona", "zip": "85006", "country": "United States", "geoPoint": {"lat": 33.44838, "lon": -112.07404}}, {"facility": "GSK Investigational Site", "city": "Phoenix", "state": "Arizona", "zip": "85013", "country": "United States", "geoPoint": {"lat": 33.44838, "lon": -112.07404}}, {"facility": "GSK Investigational Site", "city": "Scottsdale", "state": "Arizona", "zip": "85259", "country": "United States", "geoPoint": {"lat": 33.50921, "lon": -111.89903}}, {"facility": "GSK Investigational Site", "city": "Tucson", "state": "Arizona", "zip": "85712", "country": "United States", "geoPoint": {"lat": 32.22174, "lon": -110.92648}}, {"facility": "GSK Investigational Site", "city": "Little Rock", "state": "Arkansas", "zip": "72205", "country": "United States", "geoPoint": {"lat": 34.74648, "lon": -92.28959}}, {"facility": "GSK Investigational Site", "city": "Los Angeles", "state": "California", "zip": "90033", "country": "United States", "geoPoint": {"lat": 34.05223, "lon": -118.24368}}, {"facility": "GSK Investigational Site", "city": "Los Angeles", "state": "California", "zip": "90073", "country": "United States", "geoPoint": {"lat": 34.05223, "lon": -118.24368}}, {"facility": "GSK Investigational Site", "city": "Newport Beach", "state": "California", "zip": "92660", "country": "United States", "geoPoint": {"lat": 33.61891, "lon": -117.92895}}, {"facility": "GSK Investigational Site", "city": "Santa Monica", "state": "California", "zip": "90404", "country": "United States", "geoPoint": {"lat": 34.01945, "lon": -118.49119}}, {"facility": "GSK Investigational Site", "city": "Sepuldeva", "state": "California", "zip": "91343", "country": "United States", "geoPoint": {"lat": 34.16167, "lon": -118.28285}}, {"facility": "GSK Investigational Site", "city": "Washington", "state": "District of Columbia", "zip": "20037", "country": "United States", "geoPoint": {"lat": 38.89511, "lon": -77.03637}}, {"facility": "GSK Investigational Site", "city": "Hollywood", "state": "Florida", "zip": "33021", "country": "United States", "geoPoint": {"lat": 26.0112, "lon": -80.14949}}, {"facility": "GSK Investigational Site", "city": "Maitland", "state": "Florida", "zip": "32751", "country": "United States", "geoPoint": {"lat": 28.62778, "lon": -81.36312}}, {"facility": "GSK Investigational Site", "city": "Ocala", "state": "Florida", "zip": "34471", "country": "United States", "geoPoint": {"lat": 29.1872, "lon": -82.14009}}, {"facility": "GSK Investigational Site", "city": "Atlanta", "state": "Georgia", "zip": "30342", "country": "United States", "geoPoint": {"lat": 33.749, "lon": -84.38798}}, {"facility": "GSK Investigational Site", "city": "Augusta", "state": "Georgia", "zip": "30912-3200", "country": "United States", "geoPoint": {"lat": 33.47097, "lon": -81.97484}}, {"facility": "GSK Investigational Site", "city": "Marietta", "state": "Georgia", "zip": "30060", "country": "United States", "geoPoint": {"lat": 33.9526, "lon": -84.54993}}, {"facility": "GSK Investigational Site", "city": "Savannah", "state": "Georgia", "zip": "31405", "country": "United States", "geoPoint": {"lat": 32.08354, "lon": -81.09983}}, {"facility": "GSK Investigational Site", "city": "Suwanee", "state": "Georgia", "zip": "30024", "country": "United States", "geoPoint": {"lat": 34.05149, "lon": -84.0713}}, {"facility": "GSK Investigational Site", "city": "Chicago", "state": "Illinois", "zip": "60612", "country": "United States", "geoPoint": {"lat": 41.85003, "lon": -87.65005}}, {"facility": "GSK Investigational Site", "city": "Flossmoor", "state": "Illinois", "zip": "60422", "country": "United States", "geoPoint": {"lat": 41.54281, "lon": -87.68477}}, {"facility": "GSK Investigational Site", "city": "Springfield", "state": "Illinois", "zip": "62702", "country": "United States", "geoPoint": {"lat": 39.80172, "lon": -89.64371}}, {"facility": "GSK Investigational Site", "city": "Des Moines", "state": "Iowa", "zip": "50309-1426", "country": "United States", "geoPoint": {"lat": 41.60054, "lon": -93.60911}}, {"facility": "GSK Investigational Site", "city": "Wichita", "state": "Kansas", "zip": "67214", "country": "United States", "geoPoint": {"lat": 37.69224, "lon": -97.33754}}, {"facility": "GSK Investigational Site", "city": "Crestview Hills", "state": "Kentucky", "zip": "41017", "country": "United States", "geoPoint": {"lat": 39.02728, "lon": -84.58494}}, {"facility": "GSK Investigational Site", "city": "Louisville", "state": "Kentucky", "zip": "40202", "country": "United States", "geoPoint": {"lat": 38.25424, "lon": -85.75941}}, {"facility": "GSK Investigational Site", "city": "Lafayette", "state": "Louisiana", "zip": "70503", "country": "United States", "geoPoint": {"lat": 30.22409, "lon": -92.01984}}, {"facility": "GSK Investigational Site", "city": "Boston", "state": "Massachusetts", "zip": "02118", "country": "United States", "geoPoint": {"lat": 42.35843, "lon": -71.05977}}, {"facility": "GSK Investigational Site", "city": "Detroit", "state": "Michigan", "zip": "48202", "country": "United States", "geoPoint": {"lat": 42.33143, "lon": -83.04575}}, {"facility": "GSK Investigational Site", "city": "Grand Rapids", "state": "Michigan", "zip": "49525", "country": "United States", "geoPoint": {"lat": 42.96336, "lon": -85.66809}}, {"facility": "GSK Investigational Site", "city": "Traverse City", "state": "Michigan", "zip": "49684", "country": "United States", "geoPoint": {"lat": 44.76306, "lon": -85.62063}}, {"facility": "GSK Investigational Site", "city": "Minneapolis", "state": "Minnesota", "zip": "55422", "country": "United States", "geoPoint": {"lat": 44.97997, "lon": -93.26384}}, {"facility": "GSK Investigational Site", "city": "Minneapolis", "state": "Minnesota", "zip": "55455", "country": "United States", "geoPoint": {"lat": 44.97997, "lon": -93.26384}}, {"facility": "GSK Investigational Site", "city": "Chesterfield", "state": "Missouri", "zip": "63017", "country": "United States", "geoPoint": {"lat": 38.66311, "lon": -90.57707}}, {"facility": "GSK Investigational Site", "city": "Kansas City", "state": "Missouri", "zip": "64111", "country": "United States", "geoPoint": {"lat": 39.09973, "lon": -94.57857}}, {"facility": "GSK Investigational Site", "city": "Las Vegas", "state": "Nevada", "zip": "89106", "country": "United States", "geoPoint": {"lat": 36.17497, "lon": -115.13722}}, {"facility": "GSK Investigational Site", "city": "Edison", "state": "New Jersey", "zip": "08818", "country": "United States", "geoPoint": {"lat": 40.51872, "lon": -74.4121}}, {"facility": "GSK Investigational Site", "city": "West Orange", "state": "New Jersey", "zip": "07052", "country": "United States", "geoPoint": {"lat": 40.79871, "lon": -74.23904}}, {"facility": "GSK Investigational Site", "city": "Amherst", "state": "New York", "zip": "14226", "country": "United States", "geoPoint": {"lat": 42.97839, "lon": -78.79976}}, {"facility": "GSK Investigational Site", "city": "New York", "state": "New York", "zip": "10016", "country": "United States", "geoPoint": {"lat": 40.71427, "lon": -74.00597}}, {"facility": "GSK Investigational Site", "city": "Asheville", "state": "North Carolina", "zip": "28801", "country": "United States", "geoPoint": {"lat": 35.60095, "lon": -82.55402}}, {"facility": "GSK Investigational Site", "city": "Greenville", "state": "North Carolina", "zip": "27834", "country": "United States", "geoPoint": {"lat": 35.61266, "lon": -77.36635}}, {"facility": "GSK Investigational Site", "city": "Raleigh", "state": "North Carolina", "zip": "27607", "country": "United States", "geoPoint": {"lat": 35.7721, "lon": -78.63861}}, {"facility": "GSK Investigational Site", "city": "Columbus", "state": "Ohio", "zip": "43210-1250", "country": "United States", "geoPoint": {"lat": 39.96118, "lon": -82.99879}}, {"facility": "GSK Investigational Site", "city": "Oklahoma City", "state": "Oklahoma", "zip": "73104", "country": "United States", "geoPoint": {"lat": 35.46756, "lon": -97.51643}}, {"facility": "GSK Investigational Site", "city": "Oklahoma City", "state": "Oklahoma", "zip": "73112", "country": "United States", "geoPoint": {"lat": 35.46756, "lon": -97.51643}}, {"facility": "GSK Investigational Site", "city": "Philadelphia", "state": "Pennsylvania", "zip": "19107", "country": "United States", "geoPoint": {"lat": 39.95233, "lon": -75.16379}}, {"facility": "GSK Investigational Site", "city": "Philadelphia", "state": "Pennsylvania", "zip": "19140", "country": "United States", "geoPoint": {"lat": 39.95233, "lon": -75.16379}}, {"facility": "GSK Investigational Site", "city": "Pittsburgh", "state": "Pennsylvania", "zip": "15215", "country": "United States", "geoPoint": {"lat": 40.44062, "lon": -79.99589}}, {"facility": "GSK Investigational Site", "city": "Germantown", "state": "Tennessee", "zip": "38138", "country": "United States", "geoPoint": {"lat": 35.08676, "lon": -89.81009}}, {"facility": "GSK Investigational Site", "city": "Dallas", "state": "Texas", "zip": "75230", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}, {"facility": "GSK Investigational Site", "city": "Galveston", "state": "Texas", "zip": "77555", "country": "United States", "geoPoint": {"lat": 29.30135, "lon": -94.7977}}, {"facility": "GSK Investigational Site", "city": "Houston", "state": "Texas", "zip": "77005", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"facility": "GSK Investigational Site", "city": "San Antonio", "state": "Texas", "zip": "78258", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"facility": "GSK Investigational Site", "city": "Wichita Falls", "state": "Texas", "zip": "76301", "country": "United States", "geoPoint": {"lat": 33.91371, "lon": -98.49339}}, {"facility": "GSK Investigational Site", "city": "Salt Lake City", "state": "Utah", "zip": "84107", "country": "United States", "geoPoint": {"lat": 40.76078, "lon": -111.89105}}, {"facility": "GSK Investigational Site", "city": "Burlington", "state": "Vermont", "zip": "05401", "country": "United States", "geoPoint": {"lat": 44.47588, "lon": -73.21207}}, {"facility": "GSK Investigational Site", "city": "Richmond", "state": "Virginia", "zip": "23220", "country": "United States", "geoPoint": {"lat": 37.55376, "lon": -77.46026}}, {"facility": "GSK Investigational Site", "city": "Madison", "state": "Wisconsin", "zip": "53715", "country": "United States", "geoPoint": {"lat": 43.07305, "lon": -89.40123}}, {"facility": "GSK Investigational Site", "city": "Milwaukee", "state": "Wisconsin", "zip": "53215", "country": "United States", "geoPoint": {"lat": 43.0389, "lon": -87.90647}}, {"facility": "GSK Investigational Site", "city": "Capital Federal", "state": "Buenos Aires", "zip": "1181", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "GSK Investigational Site", "city": "Ciudad Autonoma de Buenos Aires", "zip": "C1221ADC", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "GSK Investigational Site", "city": "Ciudad Aut\u00f3noma de Buenos Aires", "zip": "1425", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "GSK Investigational Site", "city": "Curitiba", "state": "Paran\u00e1", "zip": "80069-900", "country": "Brazil", "geoPoint": {"lat": -25.42778, "lon": -49.27306}}, {"facility": "GSK Investigational Site", "city": "Campinas", "state": "S\u00e3o Paulo", "zip": "13083-970", "country": "Brazil", "geoPoint": {"lat": -22.90556, "lon": -47.06083}}, {"facility": "GSK Investigational Site", "city": "S\u00e3o Paulo", "zip": "05403-900", "country": "Brazil", "geoPoint": {"lat": -23.5475, "lon": -46.63611}}, {"facility": "GSK Investigational Site", "city": "Santiago", "state": "Regi\u00f3n Metro De Santiago", "zip": "7571831", "country": "Chile", "geoPoint": {"lat": -33.45694, "lon": -70.64827}}, {"facility": "GSK Investigational Site", "city": "Santiago", "state": "Regi\u00f3n Metro De Santiago", "country": "Chile", "geoPoint": {"lat": -33.45694, "lon": -70.64827}}, {"facility": "GSK Investigational Site", "city": "Singen", "state": "Baden-Wuerttemberg", "zip": "78224", "country": "Germany", "geoPoint": {"lat": 47.75935, "lon": 8.8403}}, {"facility": "GSK Investigational Site", "city": "Ulm", "state": "Baden-Wuerttemberg", "zip": "89073", "country": "Germany", "geoPoint": {"lat": 48.39841, "lon": 9.99155}}, {"facility": "GSK Investigational Site", "city": "Alzenau", "state": "Bayern", "zip": "63755", "country": "Germany"}, {"facility": "GSK Investigational Site", "city": "Bamberg", "state": "Bayern", "zip": "96047", "country": "Germany", "geoPoint": {"lat": 49.89873, "lon": 10.90067}}, {"facility": "GSK Investigational Site", "city": "Fuerth", "state": "Bayern", "zip": "90762", "country": "Germany", "geoPoint": {"lat": 49.47593, "lon": 10.98856}}, {"facility": "GSK Investigational Site", "city": "Muenchen", "state": "Bayern", "zip": "80331", "country": "Germany", "geoPoint": {"lat": 51.60698, "lon": 13.31243}}, {"facility": "GSK Investigational Site", "city": "Neuoetting", "state": "Bayern", "zip": "84524", "country": "Germany"}, {"facility": "GSK Investigational Site", "city": "Straubing", "state": "Bayern", "zip": "94315", "country": "Germany", "geoPoint": {"lat": 48.88126, "lon": 12.57385}}, {"facility": "GSK Investigational Site", "city": "Unterhaching", "state": "Bayern", "zip": "82008", "country": "Germany", "geoPoint": {"lat": 48.06598, "lon": 11.61564}}, {"facility": "GSK Investigational Site", "city": "Wuerzburg", "state": "Bayern", "zip": "97070", "country": "Germany", "geoPoint": {"lat": 49.79391, "lon": 9.95121}}, {"facility": "GSK Investigational Site", "city": "Bernau", "state": "Brandenburg", "zip": "16321", "country": "Germany", "geoPoint": {"lat": 52.67982, "lon": 13.58708}}, {"facility": "GSK Investigational Site", "city": "Ludwigsfelde", "state": "Brandenburg", "zip": "14974", "country": "Germany", "geoPoint": {"lat": 52.30322, "lon": 13.25405}}, {"facility": "GSK Investigational Site", "city": "Bad Homburg", "state": "Hessen", "zip": "61348", "country": "Germany", "geoPoint": {"lat": 50.22683, "lon": 8.61816}}, {"facility": "GSK Investigational Site", "city": "Frankfurt", "state": "Hessen", "zip": "60594", "country": "Germany", "geoPoint": {"lat": 50.11552, "lon": 8.68417}}, {"facility": "GSK Investigational Site", "city": "Wismar", "state": "Mecklenburg-Vorpommern", "zip": "23966", "country": "Germany", "geoPoint": {"lat": 53.89314, "lon": 11.45286}}, {"facility": "GSK Investigational Site", "city": "Wismar", "state": "Mecklenburg-Vorpommern", "zip": "23970", "country": "Germany", "geoPoint": {"lat": 53.89314, "lon": 11.45286}}, {"facility": "GSK Investigational Site", "city": "Bueckeburg", "state": "Niedersachsen", "zip": "31675", "country": "Germany"}, {"facility": "GSK Investigational Site", "city": "Goettingen", "state": "Niedersachsen", "zip": "37075", "country": "Germany"}, {"facility": "GSK Investigational Site", "city": "Osnabrueck", "state": "Niedersachsen", "zip": "49074", "country": "Germany"}, {"facility": "GSK Investigational Site", "city": "Baesweiler", "state": "Nordrhein-Westfalen", "zip": "52499", "country": "Germany", "geoPoint": {"lat": 50.90964, "lon": 6.18874}}, {"facility": "GSK Investigational Site", "city": "Bochum", "state": "Nordrhein-Westfalen", "zip": "44795", "country": "Germany", "geoPoint": {"lat": 51.48165, "lon": 7.21648}}, {"facility": "GSK Investigational Site", "city": "Bochum", "state": "Nordrhein-Westfalen", "zip": "44892", "country": "Germany", "geoPoint": {"lat": 51.48165, "lon": 7.21648}}, {"facility": "GSK Investigational Site", "city": "Essen", "state": "Nordrhein-Westfalen", "zip": "45122", "country": "Germany", "geoPoint": {"lat": 51.45657, "lon": 7.01228}}, {"facility": "GSK Investigational Site", "city": "Essen", "state": "Nordrhein-Westfalen", "zip": "45138", "country": "Germany", "geoPoint": {"lat": 51.45657, "lon": 7.01228}}, {"facility": "GSK Investigational Site", "city": "Hattingen", "state": "Nordrhein-Westfalen", "zip": "45525", "country": "Germany", "geoPoint": {"lat": 51.39894, "lon": 7.18557}}, {"facility": "GSK Investigational Site", "city": "Koeln", "state": "Nordrhein-Westfalen", "zip": "50767", "country": "Germany", "geoPoint": {"lat": 50.93333, "lon": 6.95}}, {"facility": "GSK Investigational Site", "city": "Moenchengladbach", "state": "Nordrhein-Westfalen", "zip": "41061", "country": "Germany", "geoPoint": {"lat": 51.18539, "lon": 6.44172}}, {"facility": "GSK Investigational Site", "city": "Muenster", "state": "Nordrhein-Westfalen", "zip": "48149", "country": "Germany", "geoPoint": {"lat": 51.96236, "lon": 7.62571}}, {"facility": "GSK Investigational Site", "city": "Limburgerhof", "state": "Rheinland-Pfalz", "zip": "67117", "country": "Germany", "geoPoint": {"lat": 49.42444, "lon": 8.39194}}, {"facility": "GSK Investigational Site", "city": "Bernburg", "state": "Sachsen-Anhalt", "zip": "06406", "country": "Germany", "geoPoint": {"lat": 51.79464, "lon": 11.7401}}, {"facility": "GSK Investigational Site", "city": "Halle", "state": "Sachsen-Anhalt", "zip": "06118", "country": "Germany", "geoPoint": {"lat": 51.48159, "lon": 11.97948}}, {"facility": "GSK Investigational Site", "city": "Koethen", "state": "Sachsen-Anhalt", "zip": "06366", "country": "Germany"}, {"facility": "GSK Investigational Site", "city": "Magdeburg", "state": "Sachsen-Anhalt", "zip": "39104", "country": "Germany", "geoPoint": {"lat": 52.12773, "lon": 11.62916}}, {"facility": "GSK Investigational Site", "city": "Magdeburg", "state": "Sachsen-Anhalt", "zip": "39124", "country": "Germany", "geoPoint": {"lat": 52.12773, "lon": 11.62916}}, {"facility": "GSK Investigational Site", "city": "Naumburg", "state": "Sachsen-Anhalt", "zip": "06618", "country": "Germany", "geoPoint": {"lat": 51.14987, "lon": 11.80979}}, {"facility": "GSK Investigational Site", "city": "Floeha", "state": "Sachsen", "zip": "09557", "country": "Germany"}, {"facility": "GSK Investigational Site", "city": "Leipzig", "state": "Sachsen", "zip": "04105", "country": "Germany", "geoPoint": {"lat": 51.33962, "lon": 12.37129}}, {"facility": "GSK Investigational Site", "city": "Leipzig", "state": "Sachsen", "zip": "04157", "country": "Germany", "geoPoint": {"lat": 51.33962, "lon": 12.37129}}, {"facility": "GSK Investigational Site", "city": "Kiel", "state": "Schleswig-Holstein", "zip": "24105", "country": "Germany", "geoPoint": {"lat": 54.32133, "lon": 10.13489}}, {"facility": "GSK Investigational Site", "city": "Jena", "state": "Thueringen", "zip": "07743", "country": "Germany", "geoPoint": {"lat": 50.92878, "lon": 11.5899}}, {"facility": "GSK Investigational Site", "city": "Berlin", "zip": "10117", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "GSK Investigational Site", "city": "Berlin", "zip": "10969", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "GSK Investigational Site", "city": "Berlin", "zip": "13353", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "GSK Investigational Site", "city": "Hamburg", "zip": "20249", "country": "Germany", "geoPoint": {"lat": 53.57532, "lon": 10.01534}}, {"facility": "GSK Investigational Site", "city": "Hamburg", "zip": "21029", "country": "Germany", "geoPoint": {"lat": 53.57532, "lon": 10.01534}}, {"facility": "GSK Investigational Site", "city": "Hamburg", "zip": "22083", "country": "Germany", "geoPoint": {"lat": 53.57532, "lon": 10.01534}}, {"facility": "GSK Investigational Site", "city": "Hamburg", "zip": "22523", "country": "Germany", "geoPoint": {"lat": 53.57532, "lon": 10.01534}}, {"facility": "GSK Investigational Site", "city": "Hamburg", "zip": "22527", "country": "Germany", "geoPoint": {"lat": 53.57532, "lon": 10.01534}}, {"facility": "GSK Investigational Site", "city": "Hyderabad, Andhra Pradesh", "zip": "500482", "country": "India"}, {"facility": "GSK Investigational Site", "city": "Lucknow", "zip": "226003", "country": "India", "geoPoint": {"lat": 26.83928, "lon": 80.92313}}, {"facility": "GSK Investigational Site", "city": "New Delhi", "country": "India", "geoPoint": {"lat": 28.63576, "lon": 77.22445}}, {"facility": "GSK Investigational Site", "city": "Daejeon", "zip": "301-721", "country": "Korea, Republic of", "geoPoint": {"lat": 36.32139, "lon": 127.41972}}, {"facility": "GSK Investigational Site", "city": "Seoul", "zip": "110-744", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "GSK Investigational Site", "city": "Seoul", "zip": "120-752", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "GSK Investigational Site", "city": "Seoul", "zip": "135-710", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "GSK Investigational Site", "city": "Seoul", "zip": "139-711", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "GSK Investigational Site", "city": "Kubang Kerian", "zip": "16150", "country": "Malaysia", "geoPoint": {"lat": 6.09123, "lon": 102.27938}}, {"facility": "GSK Investigational Site", "city": "San German", "zip": "00683", "country": "Puerto Rico", "geoPoint": {"lat": 18.08163, "lon": -67.0449}}, {"facility": "GSK Investigational Site", "city": "San Juan", "zip": "00918", "country": "Puerto Rico", "geoPoint": {"lat": 18.46633, "lon": -66.10572}}, {"facility": "GSK Investigational Site", "city": "San Juan", "zip": "00936", "country": "Puerto Rico", "geoPoint": {"lat": 18.46633, "lon": -66.10572}}, {"facility": "GSK Investigational Site", "city": "Ekaterinburg", "zip": "620102", "country": "Russian Federation", "geoPoint": {"lat": 56.8519, "lon": 60.6122}}, {"facility": "GSK Investigational Site", "city": "Moscow", "zip": "105066", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "GSK Investigational Site", "city": "Moscow", "zip": "107076", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "GSK Investigational Site", "city": "Moscow", "zip": "111539", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "GSK Investigational Site", "city": "Moscow", "zip": "117049", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "GSK Investigational Site", "city": "Moscow", "zip": "119334", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "GSK Investigational Site", "city": "Moscow", "zip": "125412", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "GSK Investigational Site", "city": "Samara", "zip": "443095", "country": "Russian Federation", "geoPoint": {"lat": 53.20007, "lon": 50.15}}, {"facility": "GSK Investigational Site", "city": "St'Petersburg", "zip": "197136", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "GSK Investigational Site", "city": "St.-Petersburg", "zip": "193019", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "GSK Investigational Site", "city": "St.-Petersburg", "zip": "194291", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "GSK Investigational Site", "city": "Kharkiv", "zip": "61068", "country": "Ukraine", "geoPoint": {"lat": 49.98081, "lon": 36.25272}}, {"facility": "GSK Investigational Site", "city": "Kyiv", "zip": "02660", "country": "Ukraine", "geoPoint": {"lat": 50.45466, "lon": 30.5238}}, {"facility": "GSK Investigational Site", "city": "Lviv", "zip": "79021", "country": "Ukraine", "geoPoint": {"lat": 49.83826, "lon": 24.02324}}]}, "referencesModule": {"references": [{"pmid": "20937567", "type": "DERIVED", "citation": "Biton V, Di Memmo J, Shukla R, Lee YY, Poverennova I, Demchenko V, Saiers J, Adams B, Hammer A, Vuong A, Messenheimer J. Adjunctive lamotrigine XR for primary generalized tonic-clonic seizures in a randomized, placebo-controlled study. Epilepsy Behav. 2010 Nov;19(3):352-8. doi: 10.1016/j.yebeh.2010.07.022. Epub 2010 Oct 30."}], "seeAlsoLinks": [{"label": "Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.", "url": "https://www.clinicalstudydatarequest.com"}], "availIpds": [{"id": "LAM100036", "type": "Informed Consent Form", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}, {"id": "LAM100036", "type": "Study Protocol", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}, {"id": "LAM100036", "type": "Annotated Case Report Form", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}, {"id": "LAM100036", "type": "Clinical Study Report", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}, {"id": "LAM100036", "type": "Individual Participant Data Set", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}, {"id": "LAM100036", "type": "Dataset Specification", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}, {"id": "LAM100036", "type": "Statistical Analysis Plan", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site."}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "The number of par. starting the CP does not equal the number completing the TP, as 1) the CP was optional, 2) not everyone from the TP was eligible to enter the CP, and 3) Baseline Failures were allowed to enter the CP, however they were not included in the \"started\" count for the TP.", "recruitmentDetails": "All participants (par.) that complete the Treatment Phase (TP) and all Baseline Failures (par. who did not meet randomization seizure criteria necessary to qualify for the TP) are eligible to enter the Continuation Phase (CP). The CP is for long-term safety exposure to lamotrigine (LTG) extended release (XR); it is not a cross-over phase.", "groups": [{"id": "FG000", "title": "Double-Blind Phase: Placebo", "description": "Control - matching placebo once daily"}, {"id": "FG001", "title": "Double-Blind Phase: LTG XR", "description": "Lamotrigine (LTG) extended release (XR) once daily"}, {"id": "FG002", "title": "Continuation Phase: Placebo/LTG", "description": "Participants who received placebo in the Double-Blind Phase and then entered the CP, in which they received LTG"}, {"id": "FG003", "title": "Continuation Phase: LTG/LTG", "description": "Participants who received LTG XR in the Double-Blind Phase and then entered the CP, in which they received LTG"}, {"id": "FG004", "title": "Baseline Failures", "description": "Baseline failures who entered the CP without receiving treatment in the Double-Blind Phase. Baseline Failures were participants that successfully progressed through the Screening Phase and completed the Baseline Phase of the Double-blind Study, but ultimately did not meet the seizure frequency criteria for randomization into the Double-Blind Treatment Phase of the study. As a result, they were not counted as having started in the Double-Blind Study, but were eligible to enter the CP of the study."}], "periods": [{"title": "Double-Blind Phase", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "77"}, {"groupId": "FG001", "numSubjects": "76"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "69"}, {"groupId": "FG001", "numSubjects": "66"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "10"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}]}, {"type": "Pregnancy", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}]}, {"type": "Participant Did Not Take Drug", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "4"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}]}]}, {"title": "Continuation Phase", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "69"}, {"groupId": "FG003", "comment": "One participant did not complete the Double-Blind Phase but was enrolled in the Continuation Phase.", "numSubjects": "67"}, {"groupId": "FG004", "numSubjects": "32"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "63"}, {"groupId": "FG003", "numSubjects": "65"}, {"groupId": "FG004", "numSubjects": "27"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "6"}, {"groupId": "FG003", "numSubjects": "2"}, {"groupId": "FG004", "numSubjects": "5"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "2"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "1"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "1"}, {"groupId": "FG004", "numSubjects": "1"}]}, {"type": "Pregnancy", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "1"}, {"groupId": "FG004", "numSubjects": "0"}]}, {"type": "Non-compliance", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Double-Blind Phase: Placebo", "description": "Control - matching placebo once daily"}, {"id": "BG001", "title": "Double-Blind Phase: LTG XR", "description": "LTG XR once daily"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "73"}, {"groupId": "BG001", "value": "70"}, {"groupId": "BG002", "value": "143"}]}], "measures": [{"title": "Age, Continuous", "description": "Baseline measures are on the Intent-to-Treat (ITT) Population, participants who took at least 1 dose of study drug and had at least 1 post-baseline efficacy assessment. Four and six participants did not meet the ITT definition in the Double-Blind Treatment Phase Placebo Arm and the Double-Blind Treatment Phase LTG XR Arm, respectively.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "28.4", "spread": "11.48"}, {"groupId": "BG001", "value": "29.4", "spread": "12.78"}, {"groupId": "BG002", "value": "28.9", "spread": "12.10"}]}]}]}, {"title": "Gender", "description": "Baseline measures are on the Intent-to-Treat (ITT) Population, participants who took at least 1 dose of study drug and had at least 1 post-baseline efficacy assessment. Four and six participants did not meet the ITT definition in the Double-Blind Treatment Phase Placebo Arm and the Double-Blind Treatment Phase LTG XR Arm, respectively.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "38"}, {"groupId": "BG001", "value": "32"}, {"groupId": "BG002", "value": "70"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "35"}, {"groupId": "BG001", "value": "38"}, {"groupId": "BG002", "value": "73"}]}]}]}, {"title": "Race/Ethnicity, Customized", "description": "Baseline measures are on the Intent-to-Treat (ITT) Population, participants who took at least 1 dose of study drug and had at least 1 post-baseline efficacy assessment. Four and six participants did not meet the ITT definition in the Double-Blind Treatment Phase Placebo Arm and the Double-Blind Treatment Phase LTG XR Arm, respectively.", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "African American/African Heritage", "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "3"}]}]}, {"title": "Asian", "categories": [{"measurements": [{"groupId": "BG000", "value": "31"}, {"groupId": "BG001", "value": "31"}, {"groupId": "BG002", "value": "62"}]}]}, {"title": "White", "categories": [{"measurements": [{"groupId": "BG000", "value": "38"}, {"groupId": "BG001", "value": "37"}, {"groupId": "BG002", "value": "75"}]}]}, {"title": "American Indian or Alaskan Native and White", "categories": [{"measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "2"}]}]}, {"title": "Asian and White", "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "1"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Percent Change From Baseline in Weekly Primary Generalized Tonic-clonic (PGTC) Seizure Frequency During the Entire Double-Blind Treatment Phase", "description": "Percent change from baseline is calculated as the number of seizures by week during the Double-Blind Treatment Phase (Treatment Week 1 up to Week 19) compared to the number of seizures per week during the Baseline Phase (Baseline Week 1 up to Week 8). A positive number equals a reduction in seizure frequency. PGTC seizures are more commonly known as gran mal seizures.", "populationDescription": "Intent-to-Treat (ITT) Population: all randomized participants who took at least one dose of study drug and had at least one post-baseline efficacy assessment in the Double-Blind Treatment Phase. One participant in each treatment group did not have any PGTC seizures during the Baseline Phase.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Full Range", "unitOfMeasure": "percent change", "timeFrame": "Baseline through end of Double-Blind Treatment Phase (up to Week 19)", "groups": [{"id": "OG000", "title": "Double-Blind Phase: Placebo", "description": "Control - matching placebo once daily"}, {"id": "OG001", "title": "Double-Blind Phase: LTG XR", "description": "LTG XR once daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "72"}, {"groupId": "OG001", "value": "69"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "32.1", "lowerLimit": "-427", "upperLimit": "100"}, {"groupId": "OG001", "value": "75.4", "lowerLimit": "-100", "upperLimit": "100"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Cochran-Mantel-Haenszel", "paramType": "Median Difference (Final Values)", "paramValue": "31.6", "ciPctValue": "95", "ciLowerLimit": "15.8", "ciUpperLimit": "48.1"}]}, {"type": "SECONDARY", "title": "Number of Participants With >=25%, >=50%, >=75%, or 100% Reduction in PGTC Seizure Frequency During the Entire Double-Blind (DB)Treatment Phase (TP), the Escalation Phase, the Maintenance Phase, and the Last 8 Weeks of the Maintenance Phase", "description": "Change in seizure frequency was calculated as the average seizure frequency during each of the following: the Entire DB Treatment Phase (Treatment Week 1 up to Week 19); the Escalation Phase (Treatment Week 1 up to Week 7); the Maintenance Phase (Treatment Week 8 up to Week 19); and the last 8 weeks of the Maintenance Phase (Treatment Week 12 up to Week 19), minus the seizure frequency at Baseline.", "populationDescription": "ITT Population. One participant in each treatment group did not have any PGTC seizures during the Baseline Phase, as a result they were not counted in this efficacy endpoint; an additional 2 and 1 participants in the Placebo and LTG XR group, respectively, were not counted in the Maintenance Phase (MP) or last 8 weeks of MP due to study withdrawal.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Entire DB Treatment Phase (Treatment Week 1 up to Week 19), Escalation Phase (Treatment Week 1 up to Week 7), Maintenance Phase (Treatment Week 8 up to Week 19), and the last 8 weeks of the Maintenance Phase (Treatment Week 12 up to Week 19)", "groups": [{"id": "OG000", "title": "Double-Blind Phase: Placebo", "description": "Control - matching placebo once daily"}, {"id": "OG001", "title": "Double-Blind Phase: LTG XR", "description": "LTG XR once daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "72"}, {"groupId": "OG001", "value": "69"}]}], "classes": [{"title": ">=25% reduction, Entire DB TP, n=72, 69", "categories": [{"measurements": [{"groupId": "OG000", "value": "43"}, {"groupId": "OG001", "value": "56"}]}]}, {"title": ">=50% reduction, Entire DB TP, n=72, 69", "categories": [{"measurements": [{"groupId": "OG000", "value": "23"}, {"groupId": "OG001", "value": "48"}]}]}, {"title": ">=75% reduction, Entire DB TP, n=72, 69", "categories": [{"measurements": [{"groupId": "OG000", "value": "14"}, {"groupId": "OG001", "value": "35"}]}]}, {"title": "100% reduction, Entire DB TP, n=72, 69", "categories": [{"measurements": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "14"}]}]}, {"title": ">=25% reduction, Escalation Phase, n=72, 69", "categories": [{"measurements": [{"groupId": "OG000", "value": "39"}, {"groupId": "OG001", "value": "51"}]}]}, {"title": ">=50% reduction, Escalation Phase, n=72, 69", "categories": [{"measurements": [{"groupId": "OG000", "value": "23"}, {"groupId": "OG001", "value": "38"}]}]}, {"title": ">=75% reduction, Escalation Phase, n=72, 69", "categories": [{"measurements": [{"groupId": "OG000", "value": "14"}, {"groupId": "OG001", "value": "24"}]}]}, {"title": "100% reduction, Escalation Phase, n=72, 69", "categories": [{"measurements": [{"groupId": "OG000", "value": "9"}, {"groupId": "OG001", "value": "15"}]}]}, {"title": ">=25% reduction, Maintenance Phase, n=70, 68", "categories": [{"measurements": [{"groupId": "OG000", "value": "46"}, {"groupId": "OG001", "value": "60"}]}]}, {"title": ">=50% reduction, Maintenance Phase, n=70, 68", "categories": [{"measurements": [{"groupId": "OG000", "value": "29"}, {"groupId": "OG001", "value": "51"}]}]}, {"title": ">=75% reduction, Maintenance Phase, n=70, 68", "categories": [{"measurements": [{"groupId": "OG000", "value": "14"}, {"groupId": "OG001", "value": "40"}]}]}, {"title": "100% reduction, Maintenance Phase, n=70, 68", "categories": [{"measurements": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "31"}]}]}, {"title": ">=25% reduction, Last 8 Weeks of MP, n=70, 68", "categories": [{"measurements": [{"groupId": "OG000", "value": "47"}, {"groupId": "OG001", "value": "61"}]}]}, {"title": ">=50% reduction, Last 8 Weeks of MP, n=70, 68", "categories": [{"measurements": [{"groupId": "OG000", "value": "29"}, {"groupId": "OG001", "value": "54"}]}]}, {"title": ">=75% reduction, Last 8 Weeks of MP, n=70, 68", "categories": [{"measurements": [{"groupId": "OG000", "value": "18"}, {"groupId": "OG001", "value": "44"}]}]}, {"title": "100% reduction, Last 8 Weeks of MP, n=70, 68", "categories": [{"measurements": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "35"}]}]}]}, {"type": "SECONDARY", "title": "Percent Change From Baseline in PGTC Seizure Frequency During the Escalation Phase, the Maintenance Phase, and During the Last 8 Weeks of the Maintenance Phase of the Double-Blind Treatment Phase", "description": "Percent change from baseline is calculated as the number of seizures by week during the Escalation Phase (Treatment Week 1 up to Week 7), the Maintenance Phase (Treatment Week 8 up to Week 19), and during the last 8 weeks of the Maintenance Phase (Treatment Week 12 up to Week 19) compared to the number of seizures per week during the Baseline Phase (Baseline Week 1 up to Week 8). A positive number equals a reduction in seizure frequency.", "populationDescription": "ITT Population. One participant in each treatment group did not have any PGTC seizures during the Baseline Phase as a result they were not counted for this efficacy endpoint; an additional 2 and 1 participants in the Placebo and LTG XR group, respectively, were not counted in the Maintenance Phase (MP) or last 8 weeks of MP due to study withdrawal.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Full Range", "unitOfMeasure": "percent change", "timeFrame": "Escalation Phase (Treatment Week 1 up to Week 7), Maintenance Phase (Treatment Week 8 up to Week 19), and the last 8 weeks of the Maintenance Phase (Week 12 up to Week 19)", "groups": [{"id": "OG000", "title": "Double-Blind Phase: Placebo", "description": "Control - matching placebo once daily"}, {"id": "OG001", "title": "Double-Blind Phase: LTG XR", "description": "LTG XR once daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "72"}, {"groupId": "OG001", "value": "69"}]}], "classes": [{"title": "Escalation Phase, n=72, 69", "categories": [{"measurements": [{"groupId": "OG000", "value": "30.6", "lowerLimit": "-319", "upperLimit": "100"}, {"groupId": "OG001", "value": "61.9", "lowerLimit": "-197", "upperLimit": "100"}]}]}, {"title": "Maintenance Phase, n=70, 68", "categories": [{"measurements": [{"groupId": "OG000", "value": "33.3", "lowerLimit": "-492", "upperLimit": "100"}, {"groupId": "OG001", "value": "89.7", "lowerLimit": "-142", "upperLimit": "100"}]}]}, {"title": "Last 8 weeks of the Maintenance Phase, n=70, 68", "categories": [{"measurements": [{"groupId": "OG000", "value": "35.4", "lowerLimit": "-180", "upperLimit": "100"}, {"groupId": "OG001", "value": "100.0", "lowerLimit": "-131", "upperLimit": "100"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With the Indicated Time to >=50% Reduction in Seizure Frequency in the Double-Blind Treatment Phase", "description": "50% reduction in seizure frequency is defined as the time at which a participant first achieved and maintained a \\>=50% reduction in seizure frequency following exposure to at least 1 week of study drug.", "populationDescription": "ITT Population", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Baseline through end of Double-Blind Treatment Phase (up to Week 19)", "groups": [{"id": "OG000", "title": "Double-Blind Phase: Placebo", "description": "Control - matching placebo once daily"}, {"id": "OG001", "title": "Double-Blind Phase: LTG XR", "description": "LTG XR once daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "73"}, {"groupId": "OG001", "value": "70"}]}], "classes": [{"title": "2 weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "22"}]}]}, {"title": "4 weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "28"}]}]}, {"title": "8 weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "14"}, {"groupId": "OG001", "value": "39"}]}]}, {"title": "12 weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "20"}, {"groupId": "OG001", "value": "43"}]}]}, {"title": "16 weeks", "categories": [{"measurements": [{"groupId": "OG000", "value": "23"}, {"groupId": "OG001", "value": "48"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Body Weight at Week 19 of the Double-Blind Treatment Phase", "description": "Change from baseline in body weight is calculated as the Week 19 (or last on-study measurement in Double-Blind Treatment Phase) value minus the Baseline value.", "populationDescription": "ITT Population", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Full Range", "unitOfMeasure": "kilograms", "timeFrame": "Baseline and Week 19 (or last on-study measurement in Double-Blind Treatment Phase)", "groups": [{"id": "OG000", "title": "Double-Blind Phase: Placebo", "description": "Control - matching placebo once daily"}, {"id": "OG001", "title": "Double-Blind Phase: LTG XR", "description": "LTG XR once daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "73"}, {"groupId": "OG001", "value": "70"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.00", "lowerLimit": "-7.7", "upperLimit": "10.0"}, {"groupId": "OG001", "value": "0.00", "lowerLimit": "-11.4", "upperLimit": "8.8"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With Improved Clinical Status on the Investigator's Global Assessment in the Double-Blind Treatment Phase", "description": "The investigators rated the participants' overall clinical status based on 7 clinical factors and an overall factor: seizure frequency, duration, and intensity; adverse experiences; social, intellectual, and motor functioning. Using a 7-point scale (marked deterioration \\[1\\], moderate deterioration \\[2\\], mild deterioration \\[3\\], no change \\[4\\], mild improvement \\[5\\], moderate improvement \\[6\\], or marked improvement \\[7\\]), the investigators assessed the participants' status compared to their condition prior to initiating study medication.", "populationDescription": "ITT Population. Overall clinical status not assessed for 2 participants in each of the Placebo and LTG XR groups, respectively.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Week 19 (or last on-study assessment in Double-Blind Treatment Phase)", "groups": [{"id": "OG000", "title": "Double-Blind Phase: Placebo", "description": "Control - matching placebo once daily"}, {"id": "OG001", "title": "Double-Blind Phase: LTG XR", "description": "LTG XR once daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "71"}, {"groupId": "OG001", "value": "68"}]}], "classes": [{"title": "Any improvement, score of 5-7", "categories": [{"measurements": [{"groupId": "OG000", "value": "36"}, {"groupId": "OG001", "value": "57"}]}]}, {"title": "No change, score of 4", "categories": [{"measurements": [{"groupId": "OG000", "value": "33"}, {"groupId": "OG001", "value": "10"}]}]}, {"title": "Any deterioration, score of 1-3", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "1"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With Improved Satisfaction With Seizure Control on the Subject Satisfaction Questionnaire in the Double-Blind Treatment Phase", "description": "Participants were asked to rate their satisfaction with their seizure control compared to their seizure control prior to initiating study drug on a 7 point scale: marked deterioration (1), moderate deterioration (2), mild deterioration (3), no change (4), mild improvement (5), moderate improvement (6), or marked improvement (7).", "populationDescription": "ITT Population. Participant satisfaction was not assessed for 2 participants in each of the Placebo and LTG XR groups, respectively.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Week 19 (or last on-study assessment in Double-Blind Treatment Phase)", "groups": [{"id": "OG000", "title": "Double-Blind Phase: Placebo", "description": "Control - matching placebo once daily"}, {"id": "OG001", "title": "Double-Blind Phase: LTG XR", "description": "LTG XR once daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "71"}, {"groupId": "OG001", "value": "68"}]}], "classes": [{"title": "Any improvement, score of 5-7", "categories": [{"measurements": [{"groupId": "OG000", "value": "53"}, {"groupId": "OG001", "value": "60"}]}]}, {"title": "No change, score of 4", "categories": [{"measurements": [{"groupId": "OG000", "value": "13"}, {"groupId": "OG001", "value": "6"}]}]}, {"title": "Any deterioration, score of 1-3", "categories": [{"measurements": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "2"}]}]}]}, {"type": "SECONDARY", "title": "Percent Change From Baseline in Weekly PGTC Seizure Frequency During the Entire Continuation Phase (CP), the Transition Phase, the Open-Label Phase, and the Last 8 Weeks of the Open-Label Phase", "description": "Percent change from baseline is calculated as the number of seizures by week during the entire CP (CP Week 1 up to Week 52), the Transition Phase (CP Week 1 up to Week 7), the Open-Label Phase (CP Week 8 up to Week 52), and the last 8 weeks of the Open-Label Phase (CP Week 45 up to Week 52) minus the number of seizures per week during the Baseline Phase (Baseline Week 1 through Week 8). A positive number equals a reduction in seizure frequency.", "populationDescription": "ITT Population for CP: all participants who took at least one dose of study medication during the CP and had at least one post baseline seizure assessment during the CP. Variability in participant numbers are due to not having any PGTC seizures during the Baseline Phase and study withdrawal prior to progressing to the next phase.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Full Range", "unitOfMeasure": "percent change", "timeFrame": "Entire CP (CP Week 1 up to Week 52), the Transition Phase (CP Week 1 up to Week 7), the Open-Label Phase (CP Week 8 up to Week 52), and the last 8 weeks of the Open-Label Phase (CP Week 45 up to Week 52)", "groups": [{"id": "OG000", "title": "Continuation Phase: Placebo/LTG", "description": "Placebo participants who entered the CP"}, {"id": "OG001", "title": "Continuation Phase: LTG/LTG", "description": "LTG XR participants who entered the CP"}, {"id": "OG002", "title": "Baseline Failures", "description": "Baseline failures who entered the CP"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "68"}, {"groupId": "OG001", "value": "66"}, {"groupId": "OG002", "value": "24"}]}], "classes": [{"title": "Entire Continuation Phase, n=68, 66, 24", "categories": [{"measurements": [{"groupId": "OG000", "value": "85.2", "lowerLimit": "-113.3", "upperLimit": "100.0"}, {"groupId": "OG001", "value": "95.1", "lowerLimit": "-100.0", "upperLimit": "100.0"}, {"groupId": "OG002", "value": "21.7", "lowerLimit": "-115.4", "upperLimit": "100.0"}]}]}, {"title": "Transition Phase, n=68, 66, 20", "categories": [{"measurements": [{"groupId": "OG000", "value": "73.1", "lowerLimit": "-90.5", "upperLimit": "100.0"}, {"groupId": "OG001", "value": "100.0", "lowerLimit": "-100.0", "upperLimit": "100.0"}, {"groupId": "OG002", "value": "100.0", "lowerLimit": "-100.0", "upperLimit": "100.0"}]}]}, {"title": "Open-Label Phase, n=68, 64, 23", "categories": [{"measurements": [{"groupId": "OG000", "value": "89.2", "lowerLimit": "-116.7", "upperLimit": "100.0"}, {"groupId": "OG001", "value": "95.0", "lowerLimit": "-100.0", "upperLimit": "100.0"}, {"groupId": "OG002", "value": "31.7", "lowerLimit": "-194.7", "upperLimit": "100.0"}]}]}, {"title": "Last 8 weeks of Open-Label Phase, n=68, 63, 19", "categories": [{"measurements": [{"groupId": "OG000", "value": "100.0", "lowerLimit": "-184.2", "upperLimit": "100.0"}, {"groupId": "OG001", "value": "100.0", "lowerLimit": "-53.3", "upperLimit": "100.0"}, {"groupId": "OG002", "value": "100.0", "lowerLimit": "-500.0", "upperLimit": "100.0"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With >=25%, >=50%, >=75%, or 100% Reduction or >=50% Increase From Baseline in Weekly PGTC Seizure Frequency for the Entire Continuation Phase, the Transition Phase, the Open-Label (OL) Phase, and the Last 8 Weeks of the OL Phase.", "description": "Change in seizure frequency was calculated as the average seizure frequency during each of the following: the Entire CP (CP Week 1 up to Week 52); the Transition Phase (CP Week 1 up to Week 7); the Open-Label (OL) Phase (CP Week 8 up to Week 52); and the last 8 weeks of the Open Label Phase (CP Week 45 up to Week 52) minus the seizure frequency at Baseline. W, Week.", "populationDescription": "ITT Population for CP. Variability in participant numbers are due to not having any PGTC seizures during the Baseline Phase and study withdrawal prior to progressing to the next phase.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Entire CP (CP Week 1 up to Week 52), the Transition Phase (CP Week 1 up to Week 7), the Open-Label Phase (CP Week 8 up to Week 52), and the last 8 weeks of the Open-Label Phase (CP Week 45 up to Week 52)", "groups": [{"id": "OG000", "title": "Continuation Phase: Placebo/LTG", "description": "Placebo participants who entered the CP"}, {"id": "OG001", "title": "Continuation Phase: LTG/LTG", "description": "LTG XR participants who entered the CP"}, {"id": "OG002", "title": "Baseline Failures", "description": "Baseline failures who entered the CP"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "68"}, {"groupId": "OG001", "value": "66"}, {"groupId": "OG002", "value": "24"}]}], "classes": [{"title": ">=25% reduction, Entire CP, n=68, 66, 24", "categories": [{"measurements": [{"groupId": "OG000", "value": "59"}, {"groupId": "OG001", "value": "63"}, {"groupId": "OG002", "value": "11"}]}]}, {"title": ">=50% reduction, Entire CP, n=68, 66, 24", "categories": [{"measurements": [{"groupId": "OG000", "value": "57"}, {"groupId": "OG001", "value": "59"}, {"groupId": "OG002", "value": "11"}]}]}, {"title": ">=75% reduction, Entire CP, n=68, 66, 24", "categories": [{"measurements": [{"groupId": "OG000", "value": "46"}, {"groupId": "OG001", "value": "49"}, {"groupId": "OG002", "value": "8"}]}]}, {"title": "100% reduction, Entire CP, n=68, 66, 24", "categories": [{"measurements": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "28"}, {"groupId": "OG002", "value": "6"}]}]}, {"title": ">=50% increase, Entire CP, n=68, 66, 24", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "10"}]}]}, {"title": ">=25% reduction, Transition Phase, n=68, 66, 20", "categories": [{"measurements": [{"groupId": "OG000", "value": "51"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "13"}]}]}, {"title": ">=50% reduction, Transition Phase, n=68, 66, 20", "categories": [{"measurements": [{"groupId": "OG000", "value": "44"}, {"groupId": "OG001", "value": "56"}, {"groupId": "OG002", "value": "12"}]}]}, {"title": ">=75% reduction, Transition Phase, n=68, 66, 20", "categories": [{"measurements": [{"groupId": "OG000", "value": "33"}, {"groupId": "OG001", "value": "46"}, {"groupId": "OG002", "value": "12"}]}]}, {"title": "100% reduction, Transition Phase, n=68, 66, 20", "categories": [{"measurements": [{"groupId": "OG000", "value": "27"}, {"groupId": "OG001", "value": "41"}, {"groupId": "OG002", "value": "12"}]}]}, {"title": ">=50% increase, Transition Phase, n=68, 66, 20", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "3"}]}]}, {"title": ">=25% reduction, Open-Label Phase, n=68, 64, 23", "categories": [{"measurements": [{"groupId": "OG000", "value": "61"}, {"groupId": "OG001", "value": "61"}, {"groupId": "OG002", "value": "12"}]}]}, {"title": ">=50% reduction, Open-Label Phase, n=68, 64, 23", "categories": [{"measurements": [{"groupId": "OG000", "value": "56"}, {"groupId": "OG001", "value": "57"}, {"groupId": "OG002", "value": "10"}]}]}, {"title": ">=75% reduction, Open-Label Phase, n=68, 64, 23", "categories": [{"measurements": [{"groupId": "OG000", "value": "47"}, {"groupId": "OG001", "value": "49"}, {"groupId": "OG002", "value": "8"}]}]}, {"title": "100% reduction, Open-Label Phase, n=68, 64, 23", "categories": [{"measurements": [{"groupId": "OG000", "value": "21"}, {"groupId": "OG001", "value": "28"}, {"groupId": "OG002", "value": "6"}]}]}, {"title": ">=50% increase, Open-Label Phase, n=68, 64, 23", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "10"}]}]}, {"title": ">=25% reduction, Last 8 W of OL Phase,n=68, 63, 19", "categories": [{"measurements": [{"groupId": "OG000", "value": "60"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "10"}]}]}, {"title": ">=50% reduction, Last 8 W of OL Phase,n=68, 63, 19", "categories": [{"measurements": [{"groupId": "OG000", "value": "53"}, {"groupId": "OG001", "value": "53"}, {"groupId": "OG002", "value": "10"}]}]}, {"title": ">=75% reduction, Last 8 W of OL Phase,n=68, 63, 19", "categories": [{"measurements": [{"groupId": "OG000", "value": "45"}, {"groupId": "OG001", "value": "47"}, {"groupId": "OG002", "value": "10"}]}]}, {"title": "100% reduction, Last 8 W of OL Phase, n=68, 63, 19", "categories": [{"measurements": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "41"}, {"groupId": "OG002", "value": "10"}]}]}, {"title": ">=50% increase, Last 8 W of OL Phase, n=68, 63, 19", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "4"}]}]}]}, {"type": "SECONDARY", "title": "Mean Change From Baseline in the Profile of Mood State (POMS) Mood Disturbance Total Score at Week 19 of the Double-Blind Treatment Phase", "description": "The POMS is a self-administered 65-item questionnaire that evaluates the participants' perception of their mood state in 6 areas: tension-anxiety, depression-dejection, anger-hostility, vigor-activity, fatigue-inertia, and confusion-bewilderment. Items are rated on a 5-point Likert scale from 0 (not at all) to 4 (extremely), with higher scores indicating a more negative mood state. A total score (from 0 to 24) is obtained by summing the scores of the six domains.", "populationDescription": "ITT Population. The questionnaire was not completed by 53 and 57 participants in the Placebo and LTG XR groups, respectively. Only participants completing the questionnaire were included in the analysis of this outcome measure.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "points on a scale", "timeFrame": "Baseline and Week 19 (or last on-study measurement in Double-Blind Treatment Phase)", "groups": [{"id": "OG000", "title": "Double-Blind Phase: Placebo", "description": "Control - matching placebo once daily"}, {"id": "OG001", "title": "Double-Blind Phase: LTG XR", "description": "LTG XR once daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "20"}, {"groupId": "OG001", "value": "13"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.4", "spread": "6.97"}, {"groupId": "OG001", "value": "9.7", "spread": "8.65"}]}]}]}, {"type": "SECONDARY", "title": "Mean Change From Baseline in the Center for Epidemiological Studies-Depression Scale (CES-D) Total Score at Week 19 of the Double-Blind Treatment Phase", "description": "The 20-item CES-D questionnaire is self-administered and asks respondents to report the frequency to which the 20 events were experienced over the past week. A 4-point Likert scale is used and ranges from rarely or none of the time (0) to most or all of the time (3). The total score, a sum across the 20 items (ranging from 0 to 60), determines the extent to which a participant may be experiencing depression. Higher scores indicate a higher severity of depression.", "populationDescription": "ITT Population. The questionnaire was not completed by 64 and 59 participants in the Placebo and LTG XR groups, respectively. Only participants completing the questionnaire were included in the analysis of this outcome measure.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "points on a scale", "timeFrame": "Baseline and Week 19 (or last on-study measurement in Double-Blind Treatment Phase)", "groups": [{"id": "OG000", "title": "Double-Blind Phase: Placebo", "description": "Control - matching placebo once daily"}, {"id": "OG001", "title": "Double-Blind Phase: LTG XR", "description": "LTG XR once daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "9"}, {"groupId": "OG001", "value": "11"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.9", "spread": "2.81"}, {"groupId": "OG001", "value": "2.4", "spread": "2.54"}]}]}]}, {"type": "SECONDARY", "title": "Mean Change From Baseline in the Neurological Disorders Depression Inventory-Epilepsy (NDDI-E) 6-Item Total Score at Week 19 of the Double-Blind Treatment Phase", "description": "The NDDI-E is a self-reported questionnaire composed of 46 brief phrases/words to identify mood disorders across the spectrum of depression. It was developed to capture depressive moods that are co-morbid with the disease of epilepsy or its treatment as well as to measure the depressive state of the participant. All phrases are measured on a 4-point Likert scale of Never (1) to Always/often (4) and refer to the participants' mood over the past week. Scoring is comprised of a total mood score calculated by summing the scores of 6 specific items (from 6=never to 24=always or often).", "populationDescription": "ITT Population. The questionnaire was not completed by 65 participants in both the Placebo and LTG XR groups. Only participants completing the questionnaire were included in the analysis of this outcome measure.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "points on a scale", "timeFrame": "Baseline and Week 19 (or last on-study measurement in Double-Blind Treatment Phase)", "groups": [{"id": "OG000", "title": "Double-Blind Phase: Placebo", "description": "Control - matching placebo once daily"}, {"id": "OG001", "title": "Double-Blind Phase: LTG XR", "description": "LTG XR once daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "8"}, {"groupId": "OG001", "value": "5"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.1", "spread": "0.98"}, {"groupId": "OG001", "value": "-2.4", "spread": "1.24"}]}]}]}, {"type": "SECONDARY", "title": "Mean Change From Baseline in the Quality of Life in Epilepsy-31-P (QOLIE-31P) Overall Score at Week 19 of the Double-Blind Treatment Phase", "description": "The QOLIE-31 is a 31-item questionnaire that evaluates the participants' perception of his or her quality of life in 7 domains: seizure worry, emotional well being, energy/fatigue, cognitive functioning, medication effects, social functioning, and overall quality of life. Each domain (with scores ranging from 0 to 100) is summed and divided by the total number of questions that were answered. The overall score is derived by weighting and then summing up the seven domain scores.", "populationDescription": "ITT Population. The questionnaire was not completed by 55 participants in both the Placebo and LTG XR groups. Only participants completing the questionnaire were included in the analysis of this outcome measure.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "points on a scale", "timeFrame": "Baseline and Week 19 (or last on-study measurement in Double-Blind Treatment Phase)", "groups": [{"id": "OG000", "title": "Double-Blind Phase: Placebo", "description": "Control - matching placebo once daily"}, {"id": "OG001", "title": "Double-Blind Phase: LTG XR", "description": "LTG XR once daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "18"}, {"groupId": "OG001", "value": "15"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-6.5", "spread": "3.97"}, {"groupId": "OG001", "value": "-8.5", "spread": "4.35"}]}]}]}, {"type": "SECONDARY", "title": "Mean Change From Baseline in the Adverse Experience Profile (AEP) Total Score at Week 19 of the Double-Blind Treatment Phase", "description": "The AEP is a list of 19 items covering many possible side effects attributable to drug treatment. The participants respond by assessing how much each event has been a problem for them over the past 4 weeks (1=Never a Problem to 4=Always a Problem). Each individual item can be examined; an overall adverse events score is calculated as the sum of the scores across the 19 items. The AEP total score ranges from 19 to 76, with a higher score indicating a higher degree of adverse event severity.", "populationDescription": "ITT Population. The questionnaire was not completed by 65 participants in both the Placebo and LTG XR groups. Only participants completing the questionnaire were included in the analysis of this outcome measure.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "points on a scale", "timeFrame": "Baseline and Week 19 (or last on-study measurement in Double-Blind Treatment Phase)", "groups": [{"id": "OG000", "title": "Double-Blind Phase: Placebo", "description": "Control - matching placebo once daily"}, {"id": "OG001", "title": "Double-Blind Phase: LTG XR", "description": "LTG XR once daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "8"}, {"groupId": "OG001", "value": "5"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "3.0", "spread": "2.16"}, {"groupId": "OG001", "value": "1.4", "spread": "2.77"}]}]}]}, {"type": "SECONDARY", "title": "Mean Change From Baseline in the Seizure Severity Questionnaire (SSQ) Global Bother Score at Week 19 Double-Blind Treatment Phase", "description": "The SSQ is a self-reported instrument developed to assess the severity of seizures and seizure symptoms. The scale consists of 10 major clinical features/symptoms of seizures that the participants rate on a 7-point Likert scale (ranging from very mild/helpful/no bother at all \\[1\\] to very severe/no help/bothersome \\[7\\]). The Global Bother Domain is the primary score used for the analysis of the SSQ and has scores ranging from 1 to 7.", "populationDescription": "ITT Population. The questionnaire was not completed by 68 and 67 participants in the Placebo and LTG XR groups, respectively. Only participants completing the questionnaire were included in the analysis of this outcome measure.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "points on a scale", "timeFrame": "Baseline and Week 19 (or last on-study measurement in Double-Blind Treatment Phase)", "groups": [{"id": "OG000", "title": "Double-Blind Phase: Placebo", "description": "Control - matching placebo once daily"}, {"id": "OG001", "title": "Double-Blind Phase: LTG XR", "description": "LTG XR once daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "3"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.86", "spread": "0.84"}, {"groupId": "OG001", "value": "1.23", "spread": "1.08"}]}]}]}, {"type": "SECONDARY", "title": "Mean Change From Baseline in the Epworth Sleepiness Scale (ESS) 8-Item Total Score at Week 19 of the Double-Blind Treatment Phase", "description": "The ESS is an 8-item, self-administered questionnaire that measures excessive daytime sleepiness in adults. The instrument captures information on the extent to which the participant would be likely, or not, to fall asleep in certain situations. The stimulus question is: How likely are you to doze off or fall asleep in the following situations, in contrast to feeling just tired? Questions are answered on a 4-point scale (would never doze \\[0\\] to high chance of dozing \\[3\\]). The total score ranges from 0 to 24, where a higher score indicates a higher chance of dozing.", "populationDescription": "ITT Population. The questionnaire was not completed by 55 and 51 participants in the Placebo and LTG XR groups, respectively. Only participants completing the questionnaire were included in the analysis of this outcome measure.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "points on a scale", "timeFrame": "Baseline and Week 19 (or last on-study measurement in Double-Blind Treatment Phase)", "groups": [{"id": "OG000", "title": "Double-Blind Phase: Placebo", "description": "Control - matching placebo once daily"}, {"id": "OG001", "title": "Double-Blind Phase: LTG XR", "description": "LTG XR once daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "18"}, {"groupId": "OG001", "value": "19"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.6", "spread": "0.69"}, {"groupId": "OG001", "value": "1.0", "spread": "0.67"}]}]}]}, {"type": "SECONDARY", "title": "Serum Concentrations and Population (POP) Pharmacokinetic Parameters for Lamotrigine", "description": "Serum samples for participants on lamotrigine were analyzed with a validated analytical method based on solid phase extraction of serum followed by High-Performance Liquid Chromatography (HPLC) Mass Spectrometry (MS)/MS analysis. The lower limit of quantification (LLQ) for serum lamotrigine was 4 nanograms (ng)/milliliter (mL), using a 50 microliter (\u00b5L) aliquot of human serum with a higher limit of quantification (HLQ) of 4,000 ng/mL. PK data cannot be reported, as PK data from several different studies have been combined into one POP/PK analysis and cannot be separated by study.", "populationDescription": "PK Population: Number of participants analyzed for PK data cannot be reported, as PK data from several different studies have been combined into one POP/PK analysis and cannot be separated by study.", "reportingStatus": "POSTED", "timeFrame": "Blood samples drawn at Treatment Weeks 11, 15, and 19 (or last on-study measurement in Double-Blind Treatment Phase)", "groups": [{"id": "OG000", "title": "Double-Blind Phase: Placebo", "description": "Control - matching placebo once daily"}, {"id": "OG001", "title": "Double-Blind Phase: LTG XR", "description": "LTG XR once daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "description": "Serious adverse events (SAEs) and adverse events (AEs) were collected for all participants in the Safety Population. The Safety Population was defined as all participants who took at least one dose of study drug.", "eventGroups": [{"id": "EG000", "title": "Double-Blind Phase: Placebo", "description": "Control - matching placebo once daily", "seriousNumAffected": 0, "seriousNumAtRisk": 74, "otherNumAffected": 21, "otherNumAtRisk": 74}, {"id": "EG001", "title": "Double-Blind Phase: LTG XR", "description": "Lamotrigine (LTG) extended release (XR) once daily", "seriousNumAffected": 1, "seriousNumAtRisk": 72, "otherNumAffected": 27, "otherNumAtRisk": 72}, {"id": "EG002", "title": "Continuation Phase: Placebo/LTG", "description": "Participants who received placebo in the Double-Blind Phase and then entered the CP, in which they received LTG", "seriousNumAffected": 3, "seriousNumAtRisk": 69, "otherNumAffected": 29, "otherNumAtRisk": 69}, {"id": "EG003", "title": "Continuation Phase: LTG/LTG", "description": "Participants who received LTG XR in the Double-Blind Phase and then entered the CP, in which they received LTG", "seriousNumAffected": 3, "seriousNumAtRisk": 67, "otherNumAffected": 21, "otherNumAtRisk": 67}, {"id": "EG004", "title": "Baseline Failures", "description": "Baseline failures who entered the CP without receiving treatment in the Double-Blind Phase. Baseline Failures were participants that successfully progressed through the Screening Phase and completed the Baseline Phase of the Double-blind Study, but ultimately did not meet the seizure frequency criteria for randomization into the Double-Blind Treatment Phase of the study. As a result, they were not counted as having started in the Double-Blind Study, but were eligible to enter the CP of the study.", "seriousNumAffected": 1, "seriousNumAtRisk": 32, "otherNumAffected": 18, "otherNumAtRisk": 32}], "seriousEvents": [{"term": "Confusional state", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 72}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 67}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 32}]}, {"term": "Altered state of consciousness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 72}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 69}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 67}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 32}]}, {"term": "Ataxia", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 72}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 67}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 32}]}, {"term": "Hemiparesis", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 72}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 69}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 67}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 32}]}, {"term": "Hydrocephalus", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 72}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 69}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 67}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 32}]}, {"term": "Nystagmus", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 72}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 67}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 32}]}, {"term": "Syncope vasovagal", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 72}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 67}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 32}]}, {"term": "Bile duct cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 72}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 69}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 67}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 32}]}, {"term": "Uterine leiomyoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 72}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 67}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 32}]}, {"term": "Conversion disorder", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 72}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 69}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 67}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 32}]}, {"term": "Suicide attempt", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 72}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 67}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 32}]}, {"term": "Abdominal pain", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 72}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 67}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 32}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 72}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 67}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 32}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 72}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 67}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 32}]}, {"term": "Abortion spontaneous", "organSystem": "Pregnancy, puerperium and perinatal conditions", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 72}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 69}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 67}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 32}]}], "otherEvents": [{"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 12, "numAtRisk": 74}, {"groupId": "EG001", "numAffected": 10, "numAtRisk": 72}, {"groupId": "EG002", "numAffected": 11, "numAtRisk": 69}, {"groupId": "EG003", "numAffected": 5, "numAtRisk": 67}, {"groupId": "EG004", "numAffected": 9, "numAtRisk": 32}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 74}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 72}, {"groupId": "EG002", "numAffected": 7, "numAtRisk": 69}, {"groupId": "EG003", "numAffected": 4, "numAtRisk": 67}, {"groupId": "EG004", "numAffected": 7, "numAtRisk": 32}]}, {"term": "Tremor", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 72}, {"groupId": "EG002", "numAffected": 5, "numAtRisk": 69}, {"groupId": "EG003", "numAffected": 3, "numAtRisk": 67}, {"groupId": "EG004", "numAffected": 3, "numAtRisk": 32}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 74}, {"groupId": "EG001", "numAffected": 7, "numAtRisk": 72}, {"groupId": "EG002", "numAffected": 5, "numAtRisk": 69}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 67}, {"groupId": "EG004", "numAffected": 2, "numAtRisk": 32}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 74}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 72}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 69}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 67}, {"groupId": "EG004", "numAffected": 5, "numAtRisk": 32}]}, {"term": "Pyrexia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 74}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 72}, {"groupId": "EG002", "numAffected": 7, "numAtRisk": 69}, {"groupId": "EG003", "numAffected": 5, "numAtRisk": 67}, {"groupId": "EG004", "numAffected": 3, "numAtRisk": 32}]}, {"term": "All rash", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 74}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 72}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 69}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 67}, {"groupId": "EG004", "numAffected": 2, "numAtRisk": 32}]}, {"term": "Diplopia", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 74}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 72}, {"groupId": "EG002", "numAffected": 4, "numAtRisk": 69}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 67}, {"groupId": "EG004", "numAffected": 2, "numAtRisk": 32}]}, {"term": "Ataxia", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 72}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 69}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 67}, {"groupId": "EG004", "numAffected": 2, "numAtRisk": 32}]}, {"term": "Somnolence", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 72}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 69}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 67}, {"groupId": "EG004", "numAffected": 2, "numAtRisk": 32}]}, {"term": "Pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 74}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 72}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 69}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 67}, {"groupId": "EG004", "numAffected": 2, "numAtRisk": 32}]}, {"term": "Fatigue", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 74}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 72}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 69}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 67}, {"groupId": "EG004", "numAffected": 3, "numAtRisk": 32}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 74}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 72}, {"groupId": "EG002", "numAffected": 4, "numAtRisk": 69}, {"groupId": "EG003", "numAffected": 4, "numAtRisk": 67}, {"groupId": "EG004", "numAffected": 2, "numAtRisk": 32}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 72}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 69}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 67}, {"groupId": "EG004", "numAffected": 2, "numAtRisk": 32}]}, {"term": "Abdominal pain", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 74}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 72}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 69}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 67}, {"groupId": "EG004", "numAffected": 2, "numAtRisk": 32}]}, {"term": "Vision blurred", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 74}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 72}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 69}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 67}, {"groupId": "EG004", "numAffected": 2, "numAtRisk": 32}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial."}, "pointOfContact": {"title": "GSK Response Center", "organization": "GlaxoSmithKline", "phone": "866-435-7343"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000004827", "term": "Epilepsy"}, {"id": "D000012640", "term": "Seizures"}, {"id": "D000004829", "term": "Epilepsy, Generalized"}, {"id": "D000004830", "term": "Epilepsy, Tonic-Clonic"}], "ancestors": [{"id": "D000001927", "term": "Brain Diseases"}, {"id": "D000002493", "term": "Central Nervous System Diseases"}, {"id": "D000009422", "term": "Nervous System Diseases"}, {"id": "D000009461", "term": "Neurologic Manifestations"}], "browseLeaves": [{"id": "M7983", "name": "Epilepsy", "asFound": "Epilepsy", "relevance": "HIGH"}, {"id": "M15452", "name": "Seizures", "asFound": "Generalized Tonic-Clonic Seizures", "relevance": "HIGH"}, {"id": "M7986", "name": "Epilepsy, Tonic-Clonic", "asFound": "Epilepsy, Tonic-Clonic", "relevance": "HIGH"}, {"id": "M7985", "name": "Epilepsy, Generalized", "asFound": "Epilepsy, Tonic-", "relevance": "HIGH"}, {"id": "M5204", "name": "Brain Diseases", "relevance": "LOW"}, {"id": "M5742", "name": "Central Nervous System Diseases", "relevance": "LOW"}, {"id": "M12404", "name": "Neurologic Manifestations", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC10", "name": "Nervous System Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000077213", "term": "Lamotrigine"}], "ancestors": [{"id": "D000000927", "term": "Anticonvulsants"}, {"id": "D000002121", "term": "Calcium Channel Blockers"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000077264", "term": "Calcium-Regulating Hormones and Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000014150", "term": "Antipsychotic Agents"}, {"id": "D000014149", "term": "Tranquilizing Agents"}, {"id": "D000002492", "term": "Central Nervous System Depressants"}, {"id": "D000011619", "term": "Psychotropic Drugs"}, {"id": "D000026941", "term": "Sodium Channel Blockers"}], "browseLeaves": [{"id": "M1701", "name": "Lamotrigine", "asFound": "Muscle strength", "relevance": "HIGH"}, {"id": "M4246", "name": "Anticonvulsants", "relevance": "LOW"}, {"id": "M5398", "name": "Calcium, Dietary", "relevance": "LOW"}, {"id": "M5381", "name": "Calcium", "relevance": "LOW"}, {"id": "M5384", "name": "Calcium Channel Blockers", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M16904", "name": "Antipsychotic Agents", "relevance": "LOW"}, {"id": "M14474", "name": "Psychotropic Drugs", "relevance": "LOW"}, {"id": "M23177", "name": "Sodium Channel Blockers", "relevance": "LOW"}, {"id": "M30025", "name": "Diuretics, Potassium Sparing", "relevance": "LOW"}], "browseBranches": [{"abbrev": "ChanBlk", "name": "Channel Blockers"}, {"abbrev": "AntiConv", "name": "Anticonvulsants"}, {"abbrev": "CNSDep", "name": "Central Nervous System Depressants"}, {"abbrev": "PsychDr", "name": "Psychotropic Drugs"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "BDCA", "name": "Bone Density Conservation Agents"}]}}, "hasResults": true}